Induction Chemotherapy for Advanced Oral Cavity Cancer (2021)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.1007/s11912-021-01119-6
- Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO; PROGNÓSTICO; CARCINOMA DE CÉLULAS ESCAMOSAS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Current oncology reports
- ISSN: 1523-3790
- Volume/Número/Paginação/Ano: v. 23, n. 11, article ID 129, 7p, 2021
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
OLIVEIRA, Thiago Bueno de et al. Induction Chemotherapy for Advanced Oral Cavity Cancer. Current oncology reports, v. 23, n. 11, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11912-021-01119-6. Acesso em: 23 abr. 2024. -
APA
Oliveira, T. B. de, Marta, G. N., Castro Junior, G. de, & Kowalski, L. P. (2021). Induction Chemotherapy for Advanced Oral Cavity Cancer. Current oncology reports, 23( 11). doi:10.1007/s11912-021-01119-6 -
NLM
Oliveira TB de, Marta GN, Castro Junior G de, Kowalski LP. Induction Chemotherapy for Advanced Oral Cavity Cancer [Internet]. Current oncology reports. 2021 ; 23( 11):[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s11912-021-01119-6 -
Vancouver
Oliveira TB de, Marta GN, Castro Junior G de, Kowalski LP. Induction Chemotherapy for Advanced Oral Cavity Cancer [Internet]. Current oncology reports. 2021 ; 23( 11):[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s11912-021-01119-6 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
Informações sobre o DOI: 10.1007/s11912-021-01119-6 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas